🌎 Diageo Upgraded, Charter Communications Downgraded, AZEK Downgraded and more...

Ratings changes for Absci, Assertio, First Foundation, Kyverna Therapeutics, Alarum Technologies, Charter Communications, Biogen and more...From Digital Mavericks Media (Ad): This way out. Passive income ahead… Unsubscribe. VIEW MY PORTFOLIO July 3rd, 2024     Has Trump Finally Gone Too Far? (ad) Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news. Register For The Webinar To Discover Today's Top Stories The Meaning Behind Short Interest: Beyond the Short Squeeze Hype Open on July 4th: Retailers and airlines. Closed: Government, banks, stock market Who are Nvidia's Silent Partners? (Weiss Ratings) Savvy Investors' Rate Cut Portfolio: Bonds, Small Caps, Energy The best concerts of 2024 so far: AP's picks include Olivia Rodrigo, Bad Bunny, George Strait, SZA Generac Holdings Stock: Mixed Signals Leave Investors Uncertain To save spotted owls, US officials plan to kill hundreds of thousands of another owl species Elon's New Device is About to Shock the World (InvestorPlace) Analysts and Earnings Propel the S&P 500's Continuous Growth To save West Coast spotted owls, US officials plan to use trained shooters to kill hundreds of thousands of barred owls CrowdStrike Stock Soars, Outpacing Palo Alto in Cybersecurity US filings for jobless claims inch up modestly, but continuing claims rise for ninth straight week Quick Links MarketBeat All Access My MarketBeat Account Settings Mobile App Analyst Ratings Central Bank Gold Heist In Progress (ad) Central Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire investors are buying right along with them. Even Warren Buffett put over $500 million into gold. And with the help of a tax and penalty-free "Trump Loophole, " these investors are investing retirement into gold and other precious metals without having to put up any of their own cash. In our Free Retirement Protection Kit, we reveal all the details on how the rich use this loophole to protect and growth their retirement wealth in any economy…and show you how you can use it too. Click here to get your free copy today. Your Watchlist You have not added any stocks to your watchlist. Click here to add stocks to your watchlist. Analysts' Upgrades (ANTX) (NYSE:ANTX) was upgraded by analysts at SVB Leerink LLC from a "market perform" rating to an "outperform" rating. They now have a $5.00 price target on the stock. This represents a 134.7% upside from the current price of $2.13. Diageo (NYSE:DEO) was upgraded by analysts at Citigroup Inc. from a "neutral" rating to a "buy" rating.The current price is $127.62. First Foundation (NASDAQ:FFWM) was upgraded by analysts at DA Davidson from a "neutral" rating to a "buy" rating. They now have a $9.00 price target on the stock, up previously from $8.00. This represents a 87.5% upside from the current price of $4.80. H & M Hennes & Mauritz AB (publ) (OTCMKTS:HNNMY) was upgraded by analysts at Deutsche Bank Aktiengesellschaft from a "sell" rating to a "buy" rating.The current price is $3.05. Dorian LPG (NYSE:LPG) was upgraded by analysts at DNB Markets from a "hold" rating to a "buy" rating. They now have a $52.00 price target on the stock. This represents a 22.5% upside from the current price of $42.45. L'Oréal (OTCMKTS:LRLCY) was upgraded by analysts at Royal Bank of Canada from an "underperform" rating to a "sector perform" rating.The current price is $87.42. Pampa Energía (NYSE:PAM) was upgraded by analysts at Citigroup Inc. from a "neutral" rating to a "buy" rating. They now have a $58.00 price target on the stock, up previously from $51.00. This represents a 32.9% upside from the current price of $43.63. Permian Resources (NASDAQ:PR) was upgraded by analysts at BMO Capital Markets from a "market perform" rating to an "outperform" rating. They now have a $21.00 price target on the stock. This represents a 27.6% upside from the current price of $16.46. View today's most recent analysts' upgrades at MarketBeat.com Brace Yourself: Experts calling for Bitcoin to hit $100k (ad) For the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range. But that could change soon. Very soon. Click here to get The Crypto Bull Run Millionaire Blueprint now. Analysts' Downgrades AZEK (NYSE:AZEK) was downgraded by analysts at DA Davidson from a "buy" rating to a "neutral" rating. They now have a $44.00 price target on the stock, down previously from $57.00. This represents a 10.2% upside from the current price of $39.94. Charter Communications (NASDAQ:CHTR) was downgraded by analysts at Citigroup Inc. from a "neutral" rating to a "sell" rating. They now have a $255.00 price target on the stock, down previously from $280.00. This represents a 14.1% downside from the current price of $297.00. EQT AB (publ) (OTCMKTS:EQBBF) was downgraded by analysts at Deutsche Bank Aktiengesellschaft from a "buy" rating to a "hold" rating.The current price is $28.80. First Foundation (NASDAQ:FFWM) was downgraded by analysts at Stephens from an "overweight" rating to an "equal weight" rating.The current price is $4.80. First Foundation (NASDAQ:FFWM) was downgraded by analysts at Raymond James from a "strong-buy" rating to a "market perform" rating.The current price is $4.80. JD Sports Fashion (OTCMKTS:JDDSF) was downgraded by analysts at Barclays PLC from an "equal weight" rating to an "underweight" rating.The current price is $1.53. Liberty Broadband (NASDAQ:LBRDA) was downgraded by analysts at Citigroup Inc. from a "buy" rating to a "neutral" rating. They now have a $57.00 price target on the stock, down previously from $67.00. This represents a 4.3% upside from the current price of $54.65. Pacira BioSciences (NASDAQ:PCRX) was downgraded by analysts at Barclays PLC from an "overweight" rating to an "equal weight" rating. They now have a $25.00 price target on the stock, down previously from $38.00. This represents a 12.8% upside from the current price of $22.17. View today's most recent analysts' downgrades at MarketBeat.com One trade. One ticker. One week. (ad) Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week? Well, then you should click here to see this free training. Analysts' New Coverage Abeona Therapeutics (NASDAQ:ABEO) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $15.00 price target on the stock. This represents a 252.9% upside from the current price of $4.25. Absci (NASDAQ:ABSI) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $7.00 price target on the stock. This represents a 105.3% upside from the current price of $3.41. Alarum Technologies (NASDAQ:ALAR) is now covered by analysts at Canaccord Genuity Group Inc.. They set a "hold" rating and a $42.00 price target on the stock. This represents a 0.1% upside from the current price of $41.97. Alarum Technologies (NASDAQ:ALAR) is now covered by analysts at Canaccord Genuity Group Inc.. They set a "hold" rating and a $42.00 price target on the stock. This represents a 0.1% upside from the current price of $41.97. Assertio (NASDAQ:ASRT) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $4.00 price target on the stock. This represents a 230.6% upside from the current price of $1.21. ENI (NYSE:E) is now covered by analysts at Morgan Stanley. They set an "equal weight" rating on the stock.The current price is $31.07. Intuit (NASDAQ:INTU) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $760.00 price target on the stock. This represents a 15.8% upside from the current price of $656.20. Kamada (NASDAQ:KMDA) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $18.00 price target on the stock. This represents a 237.7% upside from the current price of $5.33. Kyverna Therapeutics (NASDAQ:KYTX) is now covered by analysts at HC Wainwright. They set a "neutral" rating and a $8.00 price target on the stock. This represents a 0.6% downside from the current price of $8.05. MGM Resorts International (NYSE:MGM) is now covered by analysts at BTIG Research. They set a "buy" rating and a $52.00 price target on the stock. This represents a 22.0% upside from the current price of $42.62. Rheinmetall (OTCMKTS:RNMBY) is now covered by analysts at Morgan Stanley. They set an "overweight" rating on the stock.The current price is $103.23. View today's most recent analysts' new coverage at MarketBeat.com Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. START YOUR 30-DAY FREE TRIAL Calendars from MarketBeat U.S. Analyst Ratings Corporate Buybacks Cryptocurrencies Dividend Declarations Earnings Announcements Economic Reports Gap Up/Down Stocks Insider Trades Initial Public Offerings (IPOs) Most Active Stocks Percentage Gainers/Decliners Sector Performance Short Interest Unusual Options Volume Unusual Trading Volume Upgrade Your Subscription Upgrade to MarketBeat All Access and receive your premium edition of MarketBeat Daily at 9:00 AM ET. UPGRADE NOW Manage Your Watchlist View and add up to five holdings to your watchlist. VIEW MY PORTFOLIO Join Our Facebook Group Join MarketBeat's free stock discussion and trading idea group on Facebook. JOIN NOW

Thank you for subscribing to MarketBeat! We empower individual investors to make better trading decisions by providing real-time financial information and objective market research. MarketBeat is a small business and email is a crucial tool for us to share information, news, trading ideas and financial products and services with our subscribers (that's you!). If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com.   If you would like to unsubscribe or change which emails you receive, you can manage your mailing preferences or unsubscribe from these emails.   © 2006-2024 MarketBeat Media, LLC. 345 N Reid Place, Suite 620, Sioux Falls, SD 57103. United States.   Today's Bonus Content: I'm giving you the name of this investment for free

Invest Now: Starpax's Cancer Breakthrough!

Unsubscribe       Starpax Biopharma Inc. has officially launched a Regulation A capital raise to finance its clinical trials on humans. The technology is conceived to tackle a major resistance problem for cancer treatments and bring hope to patients and their families worldwide.    (By clicking the link above, you are opting in to receive emails from this advertiser. You are also agreeing to the terms of our privacy policy. Unsubscribe at any time)   Read on to learn more about Starpax's revolutionary technology and the opportunity to invest.   Studies have shown that roughly 90% of the volume of a tumor receives little to no medication when it comes to current systemic cancer treatments.   Starpax Biopharma is set to address the US$901 billion solid tumor treatment market by creating the cancer treatment of the future with its never-before-seen Precision 3D Guidance Therapy, including Starpax Living Magnetodronesô and PolarTrak® technology. Reduced risk of failure and shortened expected FDA reviews. According to the FDA, 97% of clinical trials with new drugs fail, posing a substantial financial risk to investors. Since Starpax Technology is conceived to use anti-cancer molecules that are already FDA-approved and have been used in humans for years, investors face a lower risk of failure. Additionally, Starpax addresses six of the most common cancers simultaneously, increasing the number of patients available for clinical trials compared to single rare drug trials. Starpax also meets the criteria of the FDA Fast Track Program and Health Canada accelerated review standards. Both factors will speed up Starpax's trials and approvals. Living Magnetodrones, Artificial Intelligence, and Patented Magnetic Fields to treat cancer. With conventional systemic treatments, 90% of the tumor receives little or no drug due to malfunctioning and collapsed blood vessels in tumors. Starpax Living Magnetodrones are conceived to distribute drugs into the tumor without using blood vessels and can penetrate and accumulate in hypoxic zones. Hypoxic zones are key to treating cancer since that's where the cancer stem cells are located, but they can't be reached by current conventional drugs or immune cells. The PolarTrak device in which the patient is placed is conceived to use its patented magnetic fields, controlled by Starpax's AI technology, to trap the Magnetodrones transporting drugs inside the tumor and force them to spread throughout. Preclinical tests have resulted in a 100% remission rate in extremely aggressive tumors without any toxicity observed.  Business model built to scale rapidly. Starpax has engaged specialized firms in the U.S. to find the best commercial solutions to reach patients as fast as possible. The business model involves starting the deployment of 25 Starpax Cancer Treatment Centers (of the 580 needed in the U.S.) within seven years, with a forecasted EBITDA of US$348 million in Year 2 and US$12 billion in Year 7 upon FDA approval. Starpax's technology is set to revolutionize cancer care and improve the lives of patients worldwide. Be part of a mission to create a world where cancer treatment is more effective, safe and accessible.   Invest today   (By clicking the link above, you are opting in to receive emails from this advertiser. You are also agreeing to the terms of our privacy policy. Unsubscribe at any time)   The Starpax Team

This email was sent to stevenmagallanes520.nims@blogger.com by editor@dailymarketalerts.com DailyMarketAlerts c/o CLM Media LLC, 315 Ridgedale Avenue, #556, East Hanover, NJ 07936 United States    Unsubscribe | Report Spam

There are no kings in America

The decision by the Supreme Court removes virtually all limits on what the president can do.

‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌  This nation was founded on the principle that there are no kings in America. That each of us is equal before the law. That no one is above the law. Not even the President of the United States. The decision by the Supreme Court removes virtually all limits on what the President can do. It's a dangerous precedent. I know I will respect the limits of the presidential powers, but any president -- including Donald Trump -- will now be free to ignore the law. I concur with Justice Sotomayor's dissent today. She said: "In every use of official power, the President is now a king above the law… with fear for our democracy, I dissent." So should the American people dissent? I dissent. I'm asking you to help save the America we know: An America in which presidents tell the truth, uphold the law, defend democracy, and protect our fundamental freedoms. Rush a $25 contribution for the sake of our country >> If you've saved payment information with ActBlue Express, your donation will go through immediately: $25 >> $50 >> $100 >> $250 >> $500 >> Other >> Nearly four years ago, my predecessor sent a violent mob to the U.S. Capitol to stop the peaceful transfer of power. We all saw it with our own eyes. The brutal attack on the police. The ransacking of the Capitol. A mob literally hunting down the House Speaker Nancy Pelosi. Gallows erected to hang Vice President Mike Pence. I think it's fair to say, it was one of the darkest days in the history of America. So now, the American people will have to do what the Court should have been willing to do, but will not. Does this make Trump unfit for the highest office in the land? Will they entrust the presidency to Trump again knowing he'll be more emboldened to do whatever he pleases, whenever he wants? We must win this election. And to do that, all of us -- every single one of us -- are going to have to work tirelessly to defeat Donald Trump once and for all. Will you pitch in $25 to help me and Kamala defend our democracy? May God bless you all. May God help preserve our democracy. Thank you, Joe Joe Biden President of the United States This email was sent to stevenmagallanes520.nims@blogger.com​​. Thank you so much for being a supporter of President Biden and Vice President Harris. We don't want to bother you. If you'd like to only receive our most important emails, click here. If you'd like to unsubscribe from all Biden for President emails, you can click here. We sincerely thank you for your help and support. Paid for by Biden for President.

What you need to know  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌

July 03, 2024   |   Read Online A huge surprise dividend has this stock soaring What you need to know Good day, 360! Here are our top investing ideas today. These setups look primed. And JW is back in the chat room today (welcome back!) so come drop by an say hi 👋. FOCUS LIST🔎 UCAR - Up over 15% in pre after announcing strategic move into Thai market  DOYU - Up over 30% in pre after announcing special cash dividend of US$9.76 per ordinary share ANVS - 2nd day play, up over 5% in pre after announcing new data yesterday from Phase 3 Parkinson's study highlighting improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and cognition Celebrate 40% off ALL our top services! And right now All Access includes Jason's on FIRE Roadmap, valued at $2,999 yearly, at no added cost. See ALL the deals here! HOTLIST🔥 UCAR - Up over 15% in pre after announcing strategic move into Thai market  U Power Limited (UCAR) together with its subsidiaries, engages in the development, manufacture, and sale of new energy vehicles and battery swapping stations primarily in the People's Republic of China. It also offers battery swapping and sourcing, as well as technical and consultation services. In the pre-market this morning, the company announced that it had signed a Memorandum of Understanding (MoU) with Pattaya AI Terminal Co., Ltd. to jointly drive the strategic development of green logistics and electric vehicle (EV) infrastructure in Thailand. Combining Pattaya AI's advantages in logistical solutions with U Power's proprietary battery-swapping technology, the joint venture will provide electrified solutions for Thailand's commercial logistics and dedicated passenger transportation markets.  U Power will also leverage its expertise to provide commercial EVs compatible with its UOTTA technology and deploy battery swapping and charging stations for commercial EVs in key cities and logistics nodes across Thailand, enhancing logistics chain efficiency.  During the initial phase of the partnership, U Power will introduce battery swapping technology and compatible EVs. As the partnership matures, U Power intends to locally manufacture battery-swapping commercial vehicles in Thailand. These vehicles will include pickup trucks and light-duty vans for dedicated transportation routes. UCAR stock traded up over 15% in the pre-market in reaction to the news. The first target for bulls is the pre-market high at $8. Beyond that, $8.50, $9, $10 and $10.83 come into play. Below $8, targets to the downside are $7.50, $7 and then a gap fill at $6.74 with $6.20 below that.   DOYU - Up over 30% in pre after announcing special cash dividend of US$9.76 per ordinary share DouYu International Holdings Limited (DOYU) together with its subsidiaries, operates a platform on PC and mobile apps that provides interactive games and entertainment live streaming services in the People's Republic of China. Its platform connects game developers and publishers, professional eSports teams advertisers, and viewers.  In the pre-market this morning, the company announced that the Company's board of directors approved and declared a special cash dividend of US$9.76 per ordinary share, or US$9.76 per American Depositary Share ("ADS"), to holders of record of ordinary shares and ADSs as of the close of business on August 21, 2024. The aggregate amount of cash dividends to be paid will be approximately US$300 million, with payments expected to be made on or around August 30, 2024 for holders of ordinary shares and holders of ADSs. Holders of the Company's ADSs will receive the cash dividends through JPMorgan Chase Bank, N.A., the depositary, subject to the terms and conditions of the deposit agreement. The stock traded up  over 24% in the pre-market in reaction to the news.  The $15 area acted as support in the pre-market and will be an important level to watch. Above it, targets to the upside are $16, $17 and then the pre-market high at $17.47. Beyond that, targets are $18, $20 and $21.20 with $22 and $24 above that. Below $15, targets to the downside are $14, $13 and then a gap fill at $12.59. 🎯Did you miss Jeff's Bullseye of the Week?  Then you missed this… *Trading is hard, results not guaranteed and should not be expected to be replicated typically. Don't miss another Pick of the Week! ANVS - Up over 5% in pre after announcing new data from Phase 3 Parkinson's study highlighting improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and cognition Annovis Bio, Inc. (ANVS) is a clinical stage drug platform company that develops drugs to treat neurodegeneration.  The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. In the pre-market yesterday, the company announced new data from Phase 3 Parkinson's study highlighting improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and cognition after treatment with Buntanetap. Buntanetap showed dose-dependent and statistically significant improvements in cognition in the overall enrolled PD population.  Parkinson's patients with substantial cognitive decline exhibited a very pronounced improvement. The stocked closed up over 76% in yesterday's trade and is gapping up another 5% so far in the pre-market this morning. $10.25 acted as resistance in the pre-market and will be an important level to watch. Above that targets to the upside are $10.90 and then yesterday's high at $12.51. Beyond that, $14, $16 and $20 come into play. Below $10.25, targets to the downside are $9.50, a gap fill at $9.28, $9, $8, $7, $6. MARKET NEWS 📰 P.S. Make sure you text "RAGE" to (888) 404-5747 to get all of our latest HOT STOCK ideas! Questions or concerns about our products? Email Support@360wallstreet.io © Copyright 2022, RagingBull DISCLAIMER To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at https://ragingbull.com/disclaimer FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. RagingBull.com, LLC shall be entitled to recover attorneys' fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys' fees, costs and disbursements in addition to any other relief to which it may be entitled. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication.   Update your email preferences or unsubscribe here © 2024 360 WallStreet 62 Calef Hwy. #233 lee, NH 03861, United States of America Terms of Service